ZimVie Completes Acquisition by ARCHIMED, Receives $19.00 per Share in Cash

ZimVie has completed its acquisition by ARCHIMED, an investment firm focused on healthcare industries. The deal was announced on July 20, 2025, and ZimVie stockholders are entitled to receive $19.00 in cash for each share of ZimVie common stock owned. ARCHIMED plans to accelerate ZimVie's growth as a global leader in the dental implant market.

ZimVie Inc. (NASDAQ: ZIMV), a global leader in the dental implant market, has completed its acquisition by ARCHIMED, an investment firm focused exclusively on healthcare industries. The deal, announced on July 20, 2025, has transformed ZimVie into a privately held company, with ARCHIMED acquiring all outstanding ZimVie shares for $19.00 in cash per share, as described in ZimVie's acquisition announcement.

Under the terms of the acquisition, ZimVie stockholders are entitled to receive $19.00 in cash for each share of ZimVie common stock owned. As a result of the transaction, ZimVie’s common stock no longer trades on the NASDAQ stock exchange. This move signifies a strategic shift for ZimVie, as ARCHIMED aims to accelerate its growth as a global leader in the dental implant market.

André-Michel Ballester, Managing Partner at ARCHIMED, expressed his excitement about the partnership, stating, "ZimVie’s proven innovation, trusted brand, and strong clinical heritage align perfectly with ARCHIMED’s mission to support world-class healthcare companies."

Centerview Partners served as the exclusive financial advisor to ZimVie, while Cravath, Swaine & Moore LLP acted as the legal advisor. UBS Investment Bank and Latham & Watkins LLP provided financial and legal advisory services to ARCHIMED, respectively.

ZimVie, headquartered in Palm Beach Gardens, Florida, develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. With facilities around the globe, ZimVie is committed to advancing clinical science and technology foundational to restoring daily life.

ARCHIMED, with offices in Europe, North America, and Asia, is a leading investment firm focused on healthcare industries. With a mix of operational, medical, scientific, and financial expertise, ARCHIMED serves as both a strategic and financial partner to healthcare businesses, managing €8 billion across its various funds.

The acquisition of ZimVie by ARCHIMED marks a significant development in the dental implant market, positioning ZimVie for continued growth and innovation under private ownership.